Patient release criteria for low dose rate brachytherapy implants

Area of Science:

• Medical Physics
• Nuclear Medicine
• Radiation Oncology

Background:

• Current patient release policies after brachytherapy vary significantly between institutions due to a lack of a unified governing model.
• U.S. Nuclear Regulatory Commission (NRC) guidance (NUREG 1556) provides a framework for release limits but is less accurate for common low dose rate brachytherapy isotopes like Cesium-131, Iodine-125, and Palladium-103.
• The NRC guidance allows for patient-specific calculations, provided they are documented.

Purpose of the Study:

• To develop a standardized format for patient-specific dose calculations.
• To provide a reliable method for determining safe patient release criteria following low dose rate brachytherapy.
• To address the limitations of existing NUREG 1556 formalism for commonly used low dose rate brachytherapy sources.

Main Methods:

• Development of a calculation format for patient-specific effective dose equivalent.
• Application of the format to low dose rate brachytherapy isotopes (Cs-131, I-125, Pd-103).
• Comparison of calculated dose equivalents with existing regulatory frameworks.

Main Results:

• The proposed format enables accurate estimation of effective dose equivalent for low dose rate brachytherapy isotopes.
• Patient-specific calculations provide a more precise basis for release decisions compared to generalized NUREG 1556 methods for these sources.
• The developed methodology supports consistent and documented patient release protocols.

Conclusions:

• A standardized approach to patient-specific calculations is crucial for safe and consistent patient release after low dose rate brachytherapy.
• The proposed method enhances the accuracy of dose assessment for common brachytherapy isotopes, improving upon current regulatory guidance.
• Implementation of this format can lead to more uniform and evidence-based institutional policies for brachytherapy patient release.